Adjuvant gemcitabine in patients with pancreatic cancer; the CONKO-001 study
Phase of Trial: Phase III
Latest Information Update: 21 Jan 2017
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms CONKO-001
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.
- 11 Jun 2013 New trial record
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.